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Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) is a major clinical challenge, particularly in patients with human
immunodeficiency virus (HIV) co-infection. MDR-TB treatment is increasingly available, but outcomes have not been well
characterized. South Africa has provided MDR-TB treatment for a decade, and we evaluated outcomes by HIV status for
patients enrolled between 2000 and 2004 prior to anti-retroviral access.
Methods: We assessed treatment outcomes in a prospective cohort of patients with MDR-TB from eight provincial programs
providing second line drugs. World Health Organization definitions were used. Results were stratified by HIV status.
Results: Seven hundred fifty seven patients with known HIV status were included in the final analysis, and HIV infection was
documented in 287 (38%). Overall, 348 patients (46.0%) were successfully treated, 74 (9.8%) failed therapy, 177 (23.4%) died
and 158 (20.9%) defaulted. Patients with HIV were slightly younger and less likely to be male compared to HIV negative
patients. Patients with HIV were less likely to have a successful treatment outcome (40.0 vs. 49.6; P,0.05) and more likely to
die (35.2 vs. 16.2; P,0.0001). In a competing risk survival analysis, patients with HIV had a higher hazard of death (HR: 2.33,
P,0.0001). Low baseline weight (less than 45 kg and less than 60 kg) was also associated with a higher hazard of death (HR:
2.52, P,0.0001; and HR: 1.50, P,0.0001, respectively, compared to weight greater than 60 kg). Weight less than 45 kg had
higher risk of failure (HR: 3.58, P,0.01). Any change in treatment regimen was associated with a higher hazard of default
(HR: 2.86; 95% CI 1.55–5.29, P,0.001) and a lower hazard of death (HR: 0.63, P,0.05).
Conclusions: In this MDR-TB treatment program patients with HIV infection and low weight had higher hazards of death.
Overall treatment outcomes were poor. Efforts to improve treatment for MDR-TB are urgently needed.
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Introduction
Drug-resistant tuberculosis (TB) remains a growing threat to
public health despite advances made in treatment and diagnosis
over the past decade [1,2,3,4]. TB strains resistant to the first-line
drugs isoniazid and rifampin, called multidrug-resistant TB (MDR-
TB), now account for 5% of all TB cases globally. Extensively drug-
resistant (XDR) TB,has been reported from more than 58 countries
and is estimated to occur in up to 10% of MDR-TB patients [5].
Treatment of MDR-TB remains challenging and complex, and
treatment success is considerably lower than drug-susceptible TB
[6]. Sub-Saharan Africa is especially burdened with drug-resistant
TB. South Africa ranks fourth among all countries for TB incidence
[4] and TB remains the leading cause of mortality in HIV-infected
patients; South Africa has the highest number of TB deaths
attributable to HIV, at 53% [7,8,9,10,11].
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underscores the importance of effective treatment programs for
drug-resistant TB [4]. HIV co-infection complicates TB therapy
and is associated with delays in diagnosis and poorer treatment
outcomes [12,13]. Expanding access to MDR-TB therapy is
urgently needed, yet poor implementation of such therapy can
worsen the problem of XDR-TB. Understanding risk factors for
poor treatment outcomes among MDR-TB patients is necessary to
improve treatment outcomes [5,14]. Further, outcomes of MDR-
TB treatment and the impact of HIV on treatment outcomes are
not well described in South Africa. Further, while recent studies
have shown the benefit of anti-retroviral therapy during TB
treatment, integration of TB and HIV care services remains difficult
in many areas of South Africa [15]. We therefore examined a large
prospective cohort with a high prevalence of HIV across South
Africa who received a standardized second-line therapy and
programmatic management for MDR-TB to determine overall
treatment outcomes among patients with and without HIV.
Methods
Ethics Statement
The study was approved by the Ethics Committee at the South
African Medical Research Council, eight provincial level research
committees, and the Institutional Review Board of The Johns
Hopkins University Bloomberg School of Public Health.
Patients and procedures
Adults aged 18 and older who presented with at least one culture
confirmed bacteriological diagnosis of MDR-TB at one of ten
participating MDR-TB treatment centers from eight South African
provincesbetween2000and2004wereprospectivelyenrolledinthe
study. Previously treated MDR-TB cases were excluded due to
increased potential for second-line drug (SLD) resistance and
limited access of centers to SLD resistance testing. MDR-TB was
defined as growth of M. tuberculosis from sputum or another
specimen with resistance minimally to isoniazid (MIC cutpoint, 0.2
and 1 mg/l) and rifampin (MIC cutpoint, 40 mg/l). Culture and
susceptibility testing for all first line anti-tuberculosis drugs was
performed at National Health Laboratory Service (NHLS) certified
labs withan extensive internal quality assuranceprogram associated
with each treatment center. Written informed consent was obtained
from each study participant before enrollment in the cohort.
Since 2000, all MDR-TB centers in South Africa have used
standardized programmatic management of MDR-TB (DOTS-
Plus), following a uniform approach to patient management and
treatment. The program implemented standardized recording and
reporting case record forms, completed by physicians and nurses.
All treatment and other management decisions were made
according to the DOTS-Plus protocol and by the treating team.
The study team was available for clarification of study related
documentation throughout the study, but otherwise was not
involved in completion of the case record forms. All case record
were collected by the research team from the site and manually
entered into an Access database. A standardized second-line
treatment regimen was used, which included a 4 to 6 month
hospital-based intensive phase of pyrazinamide, ethambutol,
ethionamide, ofloxacin, and either amikacin or kanamycin. This
was followed by an additional 12 to 18 months of the same
regimen omitting the injectable agent and pyrazinamide in the
continuation phase. Treatment duration was based on when
culture conversion took place; therefore, if culture conversion
occurred more quickly the clinician could shorten the treatment
duration at his/her discretion. The protocol specified obtaining a
repeat culture and first line DST on hospital admission to confirm
MDR-TB. For patients who did not have baseline culture
positivity at enrollment (i.e. contaminated specimen or specimen
results not available), the clinician’s discretion determined if
MDR-TB treatment was initiated and the appropriate duration.
Time from diagnosis (i.e. date of the positive culture result at the
initial outpatient evaluation) to treatment initiation was recorded.
Weight-based dosing was used, and ethambutol was replaced with
terizidone or cycloserine when resistance was identified. HIV
testing was offered and information on previous HIV diagnoses
was obtained from participants. Antiretroviral therapy was only
available for TB patients in late 2004 and therefore had no impact
on MDR-TB cases within this cohort.
Patients were seen at regular intervals during the intensive phase
and at least monthly during the continuation phase. Any change in
treatment regimen (i.e. changes in dosing of a drug, changes in the
frequency of administration or discontinuation) throughout the
intensive or continuation phase of treatment was recorded. The
treating team assessed outcomes using criteria contained in the
study protocol and recorded data on case report forms. We
assessed all treatment outcomes as described in Laserson et al.
(2005) after completion of the study and assigned treatment
outcomes accordingly [16]. Any patients classified as treatment
failure underwent a second review for additional verification of
clinical outcome. Discrepancy was rare, but was resolved by a
discussion between members of the research team. In all
circumstances, consensus was reached and a final decision was
made by the two reviewers.
Statistical analysis
To compare treatment outcomes, we combined Completion
and Cure into a single category and defined four mutually
exclusive outcomes: Completion/Cure, Failure, Default, and
Death. Demographic and clinical data were compared using
t-tests, chi-square and Fisher’s exact test as appropriate. Differ-
ences in treatment outcomes among patients were evaluated by
HIV infection status. Time to treatment outcomes (from treatment
initiation to each outcome) was also examined by comparing their
cumulative incidence in the presence of competing risks following
methods by Gooley et al. [17] using the SAS macro COMPRISK
[18]. In the presence of multiple competing events, the cumulative
incidence, defined as the probability of observing a particular
cause of an event for an individual given a set of characteristics, is
preferred over the traditional Kaplan-Meier (KM) estimate since
KM estimates are known to be bias when events are dependent
(i.e., KM estimates assume events are independent and censors the
competing events). Cumulative incidence estimates were computed
by HIV status, and baseline weight group.
To examine multivariate factors associated with time to death,
default or failure, and to test modification of factors by HIV status,
a competing risks regression was conducted to compute cause-
specific relative hazards using the Cox proportional hazards
model. Hazard ratios and their 95% Confidence Intervals (CI) are
reported with ratios greater than 1 indicating more rapid time to a
particular event and ratios under 1 indicating slower time to an
event. Interactions with HIV status were tested for all covariates
and evaluated using the likelihood ratio statistic. All analyses were
conducted in SAS V9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Baseline characteristics
We enrolled 1,023 patients in the cohort between 2000 and
2004. Among these 757 (74%) patients had a known HIV test
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the entire cohort was 36.5 years (range 18–75). The overall mean
age for women was 33.2 years (10.4, standard deviation; S.D.),
compared to 38.8 years (10.5, S.D.) for men (P,.0001). Thirty-
eight percent of patients (n=287) had HIV infection and 62%
(n=470) were HIV negative. The majority of patients were
previously treated for TB (92%) and almost all (98%) had
pulmonary disease. Although all patients were laboratory
confirmed with MDR-TB at the referring center, repeat culture
for confirmation on hospital admission was completed in 556
(72%), therefore 28% were enrolled in the cohort using culture
results obtained at the referring treatment facility. Two hundred
ninety (28%) individuals were tested for baseline ethambutol
resistance; among these, resistance was detected in 197 subjects
(68%). The mean treatment duration for the cohort was 393 days
(204.3, S.D.).
Baseline demographic characteristics stratified by HIV status
are shown in Table 1. Patients with HIV were younger than HIV
negative patients (34.8 vs. 37.6 years; P,0.001) and were less likely
to be male (53.7 vs. 62.6%; P,0.05). The mean time from culture-
based diagnosis of MDR-TB to initiation of treatment was . two
months for both groups. The baseline weight, sputum smear
status, mycobacterial culture positivity and ethambutol resistance
did not differ between patients with and without HIV infection.
Overall Treatment Outcomes
The treatment success rate was 46% (n=348), with 21% who
were cured and 25% who completed treatment. Treatment failure
occurred in 74 patients (9.8%), 177 patients (23.4%) died during
treatment and 158 patients (20.9%) defaulted. Patients with HIV
were less likely to have a successful treatment outcome than HIV
negative patients (40% vs. 49.6%, P,0.05) and were significantly
more likely to die (35.2% vs. 16.2%, P,0.0001, (Table 2)).
Patients with HIV had a lower treatment failure rate than HIV
negative patients (4.2 vs. 13.2%, P,0.0001). Treatment duration
was significantly different between HIV positive and negative
patients (349 days vs. 419 days; P,0.0001).
Cumulative incidences estimates of each event (failure, default
or death) by HIV status, treatment regimen, and weight group are
shown in Figure 1. Although inferential comparison by strata
would not be appropriate, examining the cumulative incidence it is
evident that patients with HIV had a greater probability of earlier
death, a slightly higher probability of earlier failure and no
differences in probability of default. Death occurs substantially
earlier for persons less than 45 kgs with limited differences in
failure and default by weight group.
Our competing risk analysis (Table 3) shows that males have a
lower hazard ratio for failure (HR 0.67; 95% CI 0.46–0.98,
P,.05), but no sex differences were noted in default or death. HIV
infection is associated with a significantly increased hazard of
death (HR: 2.52; 95% CI 2.04–3.13, P,.0001) and decreased
hazard of failure (HR: 0.41; 95% CI 0.17–0.96, P,.05); however,
HIV infection was not associated with default. The lowest weight
group at baseline (,45 kg) had a higher hazard of death (HR:
2.56; 95% CI 2.06–3.18, P,.0001) and failure (HR: 3.61; 95% CI
1.53–8.53, P,.01). The intermediate weight group at baseline
(46–60 kgs) also had a higher hazard of death (HR: 1.48; 95% CI
1.26–1.74, P,.0001) and failure, although time to failure was not
statistically significant at the 0.05 level. No differences were noted
between time of diagnosis to treatment initiation for any outcome.
The hazard ratios by treatment outcome are depicted graphically
(Figure 1) for ease of interpretation. After completing this analysis,
interactions of HIV with all co-variates were tested to determine
modification of co-variates by HIV status; no significant
interactions with HIV were found.
Discussion
This study demonstrates poor treatment outcomes from a large
DOTS-Plus cohort in sub-Saharan Africa prior to the availability
of ART. Using a standardized regimen and treatment protocol,
the overall mortality rate of 23.4% is markedly higher than
mortality among MDR-TB treatment cohorts from other
countries [6,19] with similar epidemiologic characteristics. Mor-
tality was twice as high among HIV co-infected patients as patients
without HIV with a substantial probability for earlier mortality
which is consistent with the findings of other investigators [20].
This finding explains the differences noted in treatment duration
between the two groups. Further, it is also important to note that
mortality among patients without HIV infection was greater than
seen by other investigators [6]. Studies on the impact of ART in
the region have demonstrated both a reduction in TB incidence
[21] along with a survival benefit of persons receiving earlier
initiation of ART in patients with drug susceptible TB [22]. Access
to ART would likely have resulted in improved survival among
this cohort, though the impact on treatment success cannot be
Table 1. Baseline Demographic Characteristics by HIV Status.
Positive Negative p-value
N=287 N=470
Mean (SD) Mean (SD)
Age (Years) 34.8 (8.8) 37.6 (11.7) 0.0007
Pre-Treatment Weight (Kg) 50.3 (11.3) 50.2 (10.4) 0.9650
Mean (IQR) Mean (IQR)
Time from Diagnosis to 63.9 (46.0) 70.4 (48.5) 0.1847
Treatment (Days)‘ Median 50 54
n( % ) n( % )
Males 154 (53.7) 294 (62.6) 0.0157
Pre-Treatment Smear Positive 164 (57.1) 270 (57.5) 0.9346
Pre-Treatment Culture Positive* 209 (72.8) 347 (73.8) 0.7607
Ethambutol Resistance 72 (72.0) 125 (65.8) 0.2815
‘ Interval between culture positive diagnosis at initial evaluation to time of
treatment initiation in MDR-TB Hospital *All (100%) of patients had a positive
culture on initial evaluation and referral to the study. The numbers presented
here reflect repeat testing on cohort enrollment.
doi:10.1371/journal.pone.0020436.t001
Table 2. Comparison of Treatment Outcomes by HIV Status.
HIV Status
Positive Negative p-value*
N=287 N=470
n( % ) n( % )
Success 115 (40.0) 233 (49.6) ,0.05
Failure 12 (4.2) 62 (13.2) ,0.0001
Default 59 (20.6) 99 (21.1) 0.87
Death 101 (35.2) 76 (16.2) ,0.0001
*Based on Chi-Square Test.
doi:10.1371/journal.pone.0020436.t002
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addressing the severity of the MDR-TB/HIV epidemic [15,23].
This analysis demonstrates striking differences in risk of death
and failure when stratified by baseline weight and controlling for
other baseline factors. This finding is similar to other cohorts
studies throughout the world who also demonstrate a direct
relationship to low body weight and poor MDR-TB treatment
outcomes [24,25]. Little is known about the impact of weight on
adverse drug reactions or pharmacodynamics. We believe this is
an important area for continued investigation, particularly
correlations of low body weight with both adverse drug reactions
and therapeutic drug levels of MDR-TB treatments. In light of our
data demonstrating a substantial treatment delay between
establishing the diagnosis to treatment initiation, we believe
decentralized care models and more rapid diagnostic with
improved turnaround time may be appropriate interventions to
improve this issue and further study is needed.
The overall success rate of 46% is lower than reports from other
cohorts of MDR-TB patients [6,7,26]; however, differences in
HIV prevalence, treatment regimen and duration are important
considerations in making these comparisons. Another recently
published cohort of MDR-TB treatment outcomes obtained from
a single center in KwaZulu-Natal (2000 – 2003) found successful
treatment outcomes of 43%, similar to our findings [27]. This is an
important comparison, as our study does not include data from
KwaZulu-Natal. Comparing these studies, it is clear that treatment
success is poor across the entire country. A systematic review by
Orenstein and colleagues documented an overall treatment success
rate of 62% (95% CI 58%–67%) among 33 studies from around
the world. The combination of a treatment length greater than 18
months and use of directly observed therapy (DOT) throughout
treatment were associated with treatment success [6]. Although
not statistically significant, it was noted that individualized
treatment regimens offered a trend toward greater success (64%
vs. 54%, P=0.08) than a standardized approach. This study,
however, included only two of the 22 high TB burden countries
and no high TB/HIV burden countries [6]; however, another
meta-analysis by Johnston et al, which included slightly more high
burden countries including South Africa, found a similar 62%
success rate [2]. In comparison, our study findings demonstrate
poor outcomes in a program using a shorter regimen duration and
a standardized approach. The clinicians treating our patients did
not have access to SLD susceptibility testing and ethambutol
resistance was identified among 68% of patients whose isolate was
tested; it is possible that many patients received fewer than 4 active
drugs which could limit treatment efficacy [2]. One systems level
issue in South Africa that may contribute to poorer outcomes is the
time from MDR-TB diagnosis to treatment initiation. We found
an average diagnosis to treatment initiation delay of more than 2
months. We believe there are many factors that contribute to this
delay. First, a delay could be present in the notification of the
culture result from the laboratory; second, delays may have been
encountered in notifying the patient of the result and referring
him/her to the MDR-TB treatment facility; third, the availability
of an inpatient bed in an MDR-TB facility may have resulted in
additional delay. Finally, patients in our study received DOT
during the intensive phase of therapy, but many had self-
administered therapy during the continuation phase and this
could have contributed to poorer outcomes. We do note that the
majority of our cohort (92%) was re-treatment cases. Although we
did not evaluate this, a possible cause for this high rate of acquired
MDR-TB among this group is that the DOT infrastructure
requires strengthening at all levels of the TB program.
Treatment failure among this cohort approached 10%. This is
greater than rates in cohorts in settings with low HIV prevalence
(,5%) where failure rates range between 0% and 4% among new
MDR-TB patients [26]. We do not have second line drug
susceptibility results for our patients as yet, though testing is
ongoing, and we cannot therefore determine whether individuals
who failed treatment or died had XDR-TB either at baseline or
acquired during MDR treatment. In South Africa, initial and
acquired XDR-TB (re-infection during treatment) are both likely
to have been present and may have contributed to the poor
outcomes observed [28]. One particular treatment approach that
may remedy the problems associated with exogenous re-infection
from limited infection control in these settings is to pursue
community-based MDR-TB treatment. A recent evaluation within
KwaZulu-Natal demonstrated a decreased time to treatment
initiation along with a shortened time to culture conversion in
patients treated in the community [29]. In this analysis, men had a
Table 3. Competing Risk Model of Failure, Default and Death.
Failure Default Death
Hazard
Ratio 95% CI p-value
Hazard
Ratio 95% CI p-value
Hazard
Ratio 95% CI
p-
value
Age (years, centered @ 36) 1.00 0.97 1.02 0.772 1.00 0.98 1.01 0.467 1.00 0.99 1.01 0.899
Sex Males 0.67 0.46 0.98 0.041 0.88 0.51 1.54 0.659 1.12 0.87 1.43 0.377
HIV Status Positive 0.41 0.17 0.96 0.040 1.07 0.74 1.56 0.721 2.52 2.04 3.13 ,.0001
DX TX Group
(ref ,30 days):
30-60 days 1.01 0.55 1.87 0.968 1.06 0.66 1.68 0.821 1.08 0.77 1.52 0.664
.60 days 1.34 0.83 2.17 0.235 1.02 0.52 2.00 0.965 0.86 0.49 1.50 0.591
Weight Group
(ref .60 kg):
#45 kg 3.61 1.53 8.53 0.003 0.83 0.43 1.58 0.567 2.56 2.06 3.18 ,.0001
45-60 kg 2.28 0.87 6.02 0.095 0.96 0.64 1.44 0.841 1.48 1.26 1.74 ,.0001
AIC= 4854.266.
-2 Log L= 4812.266.
Test of Weight Group 1 vs 2: Wald=3.5642 p=0.0590 Wald=0.5475 p=0.4593 Wald=17.6184.
Test of DxTx* Group 1 vs 2: Wald=2.9411 p=0.0863 Wald=0.0155 p=0.9011 Wald=0.9187.
*DxTx is the time from culture diagnosis to treatment initiation.
doi:10.1371/journal.pone.0020436.t003
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were less likely to fail than women, but simply they did so less
rapidly. We speculate this may have been related to pre-treatment
health status (i.e. earlier presentation resulting in lower acuity), but
data beyond baseline weight and time from diagnosis to treatment
initiation was not available.
Although HIV infection was not associated with default in this
study, we did find a high frequency of default (just over 20%)
among both HIV positive and negative subjects. Other investiga-
tors have found similar findings in South Africa. An analysis in the
West Coast/Winelands found an overall default rate of 29%
among MDR-TB patients [30], although differences between HIV
positive and negative patients was not evaluated. While patients
who defaulted were not tracked in this study to determine the
reasons for default, we never the less believe this is a complex issue.
Evaluations of MDR-TB treatment default in South Africa have
determined that healthcare worker attitude and substance abuse to
be associated with patient default [31]. We believe in our cohort
many issues, both programmatic and treatment related, lead to
default. Our experience tells us that many patients are not
informed on referral to MDR-TB treatment centers about the
duration of therapy or, more specifically, the duration of inpatient
hospitalization. Further, adverse drug reactions are commonly
reported in the literature. Our analysis of this situation is currently
ongoing. Changes are underway by the South Africa Department
of Health to address challenges in the treatment paradigm
including community-based treatment models [32] that will likely
help to reduce the high rate of default experienced in this and
other MDR-TB cohorts.
As with any large clinical cohort study, our study has several
limitations. First, although a standard protocol and data collection
format were used, data on HIV status and CD4 counts are not
uniformly available. It is well known that TB patients in South
Africa have an exceptionally high HIV prevalence and it is
believed that MDR-TB patients have similar rates [9]. Our
current finding of 38% likely under represent the true prevalence
of HIV as a large proportion of the original cohort were not tested,
skewing results for those with documented HIV infection, who
may have been more ill. Our study excluded retreatment cases as
we did not have access to SLD resistance testing which may limit
generalizabiliy to programs that provide this standard MDR-TB
regimen to retreatment cases. Finally, data on adherence to
treatment was poorly documented, particularly during the
continuation phase of treatment. Despite these limitations, we
believe this study provides an important evaluation of treatment
outcomes in the absence of ART.
Summary
This study describes treatment outcomes from a large
prospective cohort with high HIV prevalence using a standardized
MDR-TB regimen in South Africa pre-ART. Our findings
emphasize the need for greater attention to program performance
and other interventions to reduce the substantial mortality
associated with drug-resistant tuberculosis observed here in the
absence of ART. Strengthening programs by intensely evaluating
treatment regimens, ensuring all HIV positive patients have access
to ART, adequate staffing to support true DOT, aggressive and
pro-active management of adverse drug effects, and infection
control measures to prevent transmission of MDR and XDR-TB
between patients and health care workers are all essential
interventions [28]. Community-based treatment of MDR-TB,
with sufficient staffing to assure adherence, is likely to improve
treatment outcomes and will enhance the quality of life for those
suffering from this illness. Integration of TB and HIV care, with
increased access to ART for HIV infected MDR-TB patients, is
also essential, as demonstrated by recent studies showing improved
survival when ART is started during TB therapy [33].
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